1. High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia.
- Author
-
Niu, Mingshan, Feng, Yuan, Zhang, Ninghan, Shao, Tingting, Zhang, Huihui, Wang, Rong, Yao, Yao, Yao, Ruosi, Wu, Qingyun, Cao, Jiang, Liu, Xuejiao, Liu, Yubo, and Xu, Kailin
- Subjects
- *
ACUTE myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *CANCER chemotherapy , *PATIENT selection , *HEMATOLOGIC malignancies - Abstract
Background: Acute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML. Methods: To examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens. Results: In the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS; P = 0.0086) and event-free survival (EFS; P = 0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR = 0.556, P = 0.015) and EFS (HR = 0.598, P = 0.03). In addition, allogeneic hematopoietic stem cell transplantation (allo-HSCT) circumvented the poor prognosis that was related to miR-25 downregulation with chemotherapy. The expression level pattern of miR-25 coincided with AML differentiation and proliferation, which included HOXA and HOXB cluster members, as well as the HOX cofactor MEIS1. The MYH9 gene was identified as a direct target of miR-25. Conclusions: The miR-25 levels are correlated with prognosis in AML independently of other powerful molecular markers. The expression of miR-25 may contribute to the selection of the optimal treatment regimen between chemotherapy and allo-HCST for AML patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF